Summit Therapeutics price target raised to $45 from $30 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Summit Therapeutics to $45 from $30 and keeps a Buy rating on the shares. The firm says the ivonescimab data in head and neck squamous cell carcinoma and colorectal cancer showcase expanded opportunities beyond lung cancer.